A 16-year-old patient with Charcot Marie Tooth disease in variant c.217G>C of the INF2 gene and focal glomerulosclerosis – a case report

Introduction. Charcot Marie Tooth disease (CMT) is currently one of the most commonly diagnosed and commonly hereditary sensorimotor neuropathies. Concluding from the literature, this is the first study describing the case of a patient with CMT disease in the c.217G> C variant of the INF2 gene and focal segmental glomerulosclerosis. Aim. To present a case of a 16-year-old patient suffering from CMT disease in variant c.217G> C of the INF2 gene and focal glomerulosclerosis. Description of the case. The text describes the CMT disease in a patient who underwent the WES / WGS-NGS genetic test and found a mutation within the INF2 gene at the chromosomal position hg38 14: 104701582-G> C, cDNA level c.217 G> C , notation at the p protein level (Gly73Arg). Genotype record according to Human Genome Variation Society: NM_022489.4: c. [217G> C]; [217 =]. The publication includes data on genetics, molecular mechanisms of the disease, diagnostic methods, rehabilitation and surgical treatment. Conclusion. CMT disease is a heterogeneous group of diseases caused by mutations in various genes. The incidence of this pathology has increased significantly in the last century. Currently, there are no treatments available to combat this disease, and symptomatic treatment is the only treatment available.

[1]  A. Ortega-Yago,et al.  Management of flexible cavovarus foot in patients with Charcot-Marie-Tooth disease: midterm results. , 2021, Revista espanola de cirugia ortopedica y traumatologia.

[2]  P. Aubourg,et al.  AAV2/9-mediated silencing of PMP22 prevents the development of pathological features in a rat model of Charcot-Marie-Tooth disease 1 A , 2021, Nature Communications.

[3]  M. M. López-Rodríguez,et al.  Metabolic and Functional Improvements in a Patient with Charcot-Marie-Tooth Disease Type 2 after EGCG Administration: A Case Report , 2021, Medicina.

[4]  U. Manor,et al.  Impaired Mitochondrial Mobility in Charcot-Marie-Tooth Disease , 2020, Frontiers in Cell and Developmental Biology.

[5]  M. A. Alonso,et al.  The formin INF2 in disease: progress from 10 years of research , 2020, Cellular and Molecular Life Sciences.

[6]  Anirudh Gupta,et al.  Charcot-Marie-Tooth: From Molecules to Therapy , 2019, International journal of molecular sciences.

[7]  M. Fontès Charcot Marie Tooth Disease. A Single Disorder? , 2018, International journal of molecular sciences.

[8]  C. Pupe,et al.  Pain in Charcot-Marie-Tooth disease: an update , 2017, Arquivos de Neuro-Psiquiatria.

[9]  A. Baron,et al.  Maladie de Charcot-Marie-Tooth - Éléments de rééducation fonctionnelle, kinésithérapie, ergothérapie , 2017 .

[10]  K. Refshauge,et al.  Safety and efficacy of progressive resistance exercise for Charcot-Marie-Tooth disease in children: a randomised, double-blind, sham-controlled trial. , 2017, The Lancet. Child & adolescent health.

[11]  E. Gallardo,et al.  Intermediate Charcot–Marie–Tooth disease: an electrophysiological reappraisal and systematic review , 2017, Journal of Neurology.

[12]  E. Dimitrova,et al.  The Role of Rehabilitation in the Management of Patients with Charcot-Marie-Tooth Disease: Report of Two Cases , 2016, Open access Macedonian journal of medical sciences.

[13]  B. Corrado,et al.  Rehabilitation Management of the Charcot–Marie–Tooth Syndrome , 2016, Medicine.

[14]  P. Nunes,et al.  Epidemiologic Study of Charcot-Marie-Tooth Disease: A Systematic Review , 2016, Neuroepidemiology.

[15]  Kota Watanabe [Treatment for Patients with Charcot-Marie-Tooth Disease: Orthopaedic Aspects]. , 2016, Brain and nerve = Shinkei kenkyu no shinpo.

[16]  T. Boffeli,et al.  Minimally Invasive Early Operative Treatment of Progressive Foot and Ankle Deformity Associated With Charcot-Marie-Tooth Disease. , 2015, The Journal of foot and ankle surgery : official publication of the American College of Foot and Ankle Surgeons.

[17]  Ruxu Zhang,et al.  Intermediate Charcot-Marie-Tooth disease , 2014, Neuroscience Bulletin.

[18]  D. Radice,et al.  Pain and small fiber function in charcot–marie–tooth disease type 1A , 2014, Muscle & nerve.

[19]  G. Braathen Genetic epidemiology of Charcot–Marie–Tooth disease , 2012, Acta neurologica Scandinavica. Supplementum.

[20]  G. Mollet,et al.  INF2 mutations in Charcot-Marie-Tooth disease with glomerulopathy. , 2011, The New England journal of medicine.

[21]  F. Kok,et al.  Clinical and neurophysiological investigation of a large family with dominant Charcot-Marie-Tooth type 2 disease with pyramidal signs. , 2011, Arquivos de neuro-psiquiatria.

[22]  T. Pollard,et al.  Review of the mechanism of processive actin filament elongation by formins. , 2009, Cell motility and the cytoskeleton.

[23]  Davide Pareyson,et al.  Diagnosis, natural history, and management of Charcot–Marie–Tooth disease , 2009, The Lancet Neurology.

[24]  B. Goode,et al.  Actin nucleation and elongation factors: mechanisms and interplay. , 2009, Current opinion in cell biology.

[25]  J. Lupski,et al.  MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2. , 2006, Brain : a journal of neurology.

[26]  F. Baas,et al.  Axonal neuropathy with optic atrophy is caused by mutations in mitofusin 2 , 2006, Annals of neurology.

[27]  M. Fontès,et al.  Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease , 2004, Nature Medicine.

[28]  D. Pellman,et al.  A conserved mechanism for Bni1- and mDia1-induced actin assembly and dual regulation of Bni1 by Bud6 and profilin. , 2003, Molecular biology of the cell.

[29]  V. E. Wood,et al.  Treatment of the Upper Limb in Charcot–Marie–Tooth Disease , 1995, Journal of hand surgery.

[30]  P K Thomas,et al.  The clinical features of hereditary motor and sensory neuropathy types I and II. , 1980, Brain : a journal of neurology.